Related Experiment Video
Updated: Dec 9, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
SARS-CoV-2 and the safety margins of cell-based biological medicinal products
Jens Modrof1, Astrid Kerschbaum1, Maria R Farcet1
1Global Pathogen Safety, Baxter AG (part of Takeda), Benatzkygasse 2-6, 1221, Vienna, Austria.
Abstract:
With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adventitious virus testing of fermenter harvest tested.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Clinically Relevant Drug Product Specifications: Methods of Establishment

